AI Medical Literature Synthesis Agent
This agent analyzes a corpus of scientific medical articles to produce a structured literature synthesis on a given clinical question. It evaluates evidence levels, identifies consensus and controversies, and generates actionable recommendations for clinical practice.
For who
Physicians, clinical researchers, hospital pharmacists, and medical students looking to quickly produce a rigorous literature review on a precise clinical question.
Input
Question clinique à explorer (ex : efficacité d'un traitement, comparaison de stratégies thérapeutiques) accompagnée des résumés ou textes intégraux des articles scientifiques à analyser (abstracts PubMed, PDF, ou références bibliographiques)
steps (4)
Clinical Question Framing
promptStructures the research question according to PICO format and defines inclusion criteria
Critical Article Analysis
promptEvaluates each article using critical appraisal grids and evidence levels
Evidence Synthesis
promptCross-references results to identify consensus, divergences, and gaps in the literature
Recommendations and Final Report
promptFormulates graded clinical recommendations and produces the complete synthesis report
Output
Rapport complet de synthèse de littérature comprenant : cadrage PICO, analyse critique graduée de chaque article, synthèse narrative des preuves, recommandations cliniques graduées (A/B/C/AE), tableau récapitulatif des études et perspectives de recherche
Example
Input
Clinical question: What is the efficacy of SGLT2 inhibitors (gliflozins) in reducing cardiovascular mortality in type 2 diabetic patients with heart failure with preserved ejection fraction? Articles provided: abstracts of the EMPEROR-Preserved trial (Anker 2021), DELIVER trial (Solomon 2022), Vaduganathan 2022 meta-analysis, French observational registry FASTTRACK-HF 2023.
Output
Executive summary: The synthesis of 4 studies (2 RCTs, 1 meta-analysis, 1 registry) involving 15,842 patients shows that SGLT2 inhibitors significantly reduce the composite endpoint of cardiovascular death/heart failure hospitalization (HR 0.80, 95%CI 0.73-0.87) in T2D patients with HFpEF... Recommendation 1 (Grade A): It is recommended to initiate SGLT2 inhibitor treatment in all type 2 diabetic patients with heart failure with preserved ejection fraction (LVEF > 40%), in the absence of contraindication... Recommendation 2 (Grade B): It is suggested to introduce treatment early after heart failure diagnosis, as DELIVER data suggest a benefit from the first weeks...
Customization
| Parameter | Description | Default |
|---|---|---|
| Système de gradation | Échelle de niveaux de preuve et grades de recommandation utilisée (HAS, GRADE, Oxford CEBM) | HAS (Haute Autorité de Santé) |
| Profondeur d'analyse | Niveau de détail de l'analyse critique — résumé rapide ou évaluation méthodologique exhaustive avec grilles validées | Exhaustive avec grilles CONSORT/STROBE/PRISMA |
| Langue des sources | Langues acceptées pour les articles du corpus analysé | Français et Anglais |